Minerva Neurosciences Inc (NERV)

Over the past six months, Minerva Neurosciences' stock price has seen significant fluctuations, moving between $1.15 and $12.46 over the past year, with a share price around $6.01 as of early March 2026. In early 2024, the FDA issued a Complete Response Letter regarding the NDA for roluperidone, citing the need for an additional study and a lack of data on concomitant antipsychotic administration, which impacted NERV's stock performance. Analysts have maintained a cautious stance, with adjusted price targets signaling reduced confidence. The company reported its third-quarter 2025 financial results and business updates in November 2025, and its fourth-quarter and fiscal year 2024 financial results and business updates in February 2025, noting lower R&D expenses. In February 2026, there were disclosures of significant ownership stakes, including Coastlands reporting a 9.99% stake, Logos Global disclosing a 9.9% ownership stake, and Adage Capital disclosing a 6.35% stake.

As a clinical-stage biopharmaceutical company, Minerva Neurosciences, Inc. does not experience traditional demand seasonality for its products and services. The demand for its offerings is primarily driven by the progression of its drug candidates through clinical trials, regulatory approvals, and the underlying unmet medical needs, making its performance tied to research and development milestones, clinical trial results, and regulatory decisions rather than seasonal consumer purchasing patterns.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing product candidates for central nervous system (CNS) disorders, aiming to improve therapeutic options for patients by advancing novel drug candidates in areas of significant unmet medical need, particularly focusing on negative symptoms of schizophrenia and Parkinson's disease. Roluperidone (MIN-101) is being developed for the treatment of negative symptoms in patients with schizophrenia, designed to block specific receptors involved in mood, cognition, sleep, and anxiety regulation. MIN-301, a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, is being developed for the treatment of Parkinson's disease and other neurodegenerative disorders. Seltorexant is also being developed for the treatment of insomnia disorder and as an adjunctive treatment for major depressive disorder (MDD).

Minerva Neurosciences, Inc. is headquartered in Burlington and Waltham, Massachusetts, United States. Its common stock trades on the Nasdaq Capital Market under the symbol NERV and is listed on several European stock exchanges, including Stuttgart, Frankfurt, Munich, and Dusseldorf. Minerva also has a strategic partnership with Mitsubishi Tanabe Pharma Corporation for the global development of roluperidone outside Asia.

Minerva Neurosciences' brand reputation in the past year has been largely influenced by its clinical development progress and regulatory interactions, with the FDA's Complete Response Letter for roluperidone significantly impacting public and investor perception. Analyst ratings, which have generally been "Neutral" or "Reduce," also reflect a cautious sentiment in the investment community, affecting its standing within the biopharmaceutical industry and among potential investors.

Minerva Neurosciences, Inc. has a diverse ownership structure, with retail investors holding around 55% of the shares, institutional investors holding approximately 21% to 42.45%, and hedge funds owning about 10%. Major institutional owners include Federated Hermes, Inc., Vivo Capital, LLC, Logos Global Management LP, Adage Capital Partners Gp, L.l.c., Farallon Capital Management Llc, Spruce Street Capital LP, Ally Bridge Group (NY) LLC, Acuta Capital Partners, Llc, and The Vanguard Group, Inc. Individual insider ownership also exists, with figures such as Index Venture Associates III Ltd, Care Capital III LLC, Michele Ollier, Rubertis Francesco De, Lorenzo Pellegrini, and Johnson Johnson listed as significant holders.